Evaluation CAPES Module #3: Spondyloarthritis (SpA) and Psoriatic Arthritis (PsA) Treatment Update

Demographic Questions

Question Title

* 1. Please provide your name and email address.

Name

Email Address

Question Title

* 2. What is your specialty?

Dermatology

Rheumatology

Primary Care

Other (please specify)

Question Title

* 3. Please indicate your practice setting.

Academic

Community

Question Title

* 4. Number of patients seen/impacted per week.

Activity Objectives: Please rate your level of achievement.

Question Title

* 5. Review treatment recommendations for the clinical domains of psoriatic arthritis: peripheral arthritis, spine disease, enthesitis, dactylitis, skin and nail disease, and associated conditions of inflammatory bowel disease and uveitis.

Outstanding

Good

Average

Fair

Poor

Question Title

* 6. Review data for individual drugs that have been approved or are due to be approved for PsA.

Outstanding

Good

Average

Fair

Poor

Question Title

* 7. Learn treatment options for the patient who has “tried everything.”

Outstanding

Good

Average

Fair

Poor

Question Title

* 8. Review the current treatment paradigm for axial SpA.

Outstanding

Good

Average

Fair

Poor

Question Title

* 9. Identify unmet needs and discuss future directions in the management of axial SpA.

Outstanding

Good

Average

Fair

Poor

Evaluation of the Presenters

Question Title

* 10. The delivery of the presentation given by Philip Mease, MD, was:

Outstanding

Good

Average

Fair

Poor

Question Title

* 11. The content of the presentation given by Philip Mease, MD, was:

Outstanding

Good

Average

Fair

Poor

Question Title

* 12. Did Philip Mease, MD, appear objective and unbiased by commercial interests?

Yes

If no, please explain:

Question Title

* 13. The content of the presentation given by Joerg Ermann, MD, was:

Outstanding

Good

Average

Fair

Poor

Question Title

* 14. The delivery of the presentation given by Joerg Ermann, MD, was:

Outstanding

Good

Average

Fair

Poor

Question Title

* 15. Did Joerg Ermann, MD, appear objective and unbiased by commercial interests?

Yes

If no, please explain:

Question Title

* 16. The content of the presentation given by Roz Tolliver was:

Outstanding

Good

Average

Fair

Poor

Question Title

* 17. The delivery of the presentation given by Roz Tolliver was:

Outstanding

Good

Average

Fair

Poor

Question Title

* 18. Did Roz Tolliver appear objective and unbiased by commercial interests?

Yes

If no, please explain:

Question Title

* 19. The content of the presentation given by John Latella was:

Outstanding

Good

Average

Fair

Poor

Question Title

* 20. The delivery of the presentation given by John Latella was:

Outstanding

Good

Average

Fair

Poor

Question Title

* 21. Did John Latella appear objective and unbiased by commercial interests?

Yes

If no, please explain:

Question Title

* 22. As a moderator, Atul Deodhar, MD, MRCP, was:

Outstanding

Good

Average

Fair

Poor

Relevance and Application

Question Title

* 23. Was the information in this activity relevant to your practice or professional development?

Yes

Question Title

* 24. I learned new information about SpA and PsA as a result of this program.

Yes

Question Title

* 25. Based on the information you received today, do you plan on changing your practice?

Yes, I intend to change the therapy that I render

Yes, I intend to alter the way that I evaluate my patients

Yes, I intend to change the legal/documentation/financial management of my practice

Yes, it may affect my patient referrals

No, but it did confirm my current practice

No, because it doesn’t directly apply to my practice

No, but it did increase my knowledge of community resources

No, because the information was inadequate and/or inaccurate

Other (please elaborate)

Question Title

* 26. How would you rate the presentation overall?

Outstanding

Good

Average

Fair

Poor

Evaluation CAPES Module #3: Spondyloarthritis (SpA) and Psoriatic Arthritis (PsA) Treatment Update

Question Title

* 1. Please provide your name and email address.

Question Title

* 2. What is your specialty?

Question Title

* 3. Please indicate your practice setting.

Question Title

* 4. Number of patients seen/impacted per week.

Question Title

* 5. Review treatment recommendations for the clinical domains of psoriatic arthritis: peripheral arthritis, spine disease, enthesitis, dactylitis, skin and nail disease, and associated conditions of inflammatory bowel disease and uveitis.

Question Title

* 6. Review data for individual drugs that have been approved or are due to be approved for PsA.

Question Title

* 7. Learn treatment options for the patient who has “tried everything.”

Question Title

* 8. Review the current treatment paradigm for axial SpA.

Question Title

* 9. Identify unmet needs and discuss future directions in the management of axial SpA.

Question Title

* 10. The delivery of the presentation given by Philip Mease, MD, was:

Question Title

* 11. The content of the presentation given by Philip Mease, MD, was:

Question Title

* 12. Did Philip Mease, MD, appear objective and unbiased by commercial interests?

Question Title

* 13. The content of the presentation given by Joerg Ermann, MD, was:

Question Title

* 14. The delivery of the presentation given by Joerg Ermann, MD, was:

Question Title

* 15. Did Joerg Ermann, MD, appear objective and unbiased by commercial interests?

Question Title

* 16. The content of the presentation given by Roz Tolliver was:

Question Title

* 17. The delivery of the presentation given by Roz Tolliver was:

Question Title

* 18. Did Roz Tolliver appear objective and unbiased by commercial interests?

Question Title

* 19. The content of the presentation given by John Latella was:

Question Title

* 20. The delivery of the presentation given by John Latella was:

Question Title

* 21. Did John Latella appear objective and unbiased by commercial interests?

Question Title

* 22. As a moderator, Atul Deodhar, MD, MRCP, was:

Question Title

* 23. Was the information in this activity relevant to your practice or professional development?

Question Title

* 24. I learned new information about SpA and PsA as a result of this program.

Question Title

* 25. Based on the information you received today, do you plan on changing your practice?

Question Title

* 26. How would you rate the presentation overall?

Question Title

* 27. Please let us know about any other comments you have: